An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...

The Colorado House of Representatives has given its final approval to a bill that would allow a form of psilocybin to be prescribed as a medication if the federal government authorizes its use. About ...

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

A Senate committee in Virginia has advanced legislation that would fund clinical trials involving veterans and “breakthrough therapies” as designated by the Food and Drug Administration (FDA), ...

Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.